金双岐联合思密达治疗小儿腹泻的临床疗效及安全性分析  

Clinical effect and safety of golden bifid and smecta in the treatment of infantile diarrhea

作　　者：卢娟毅 LU Juan-yi(Chang＇an District Maternal and Child Health Hospital, Xi＇an 710100, China)

机构地区：[1]西安长安区妇幼保健院,陕西西安710100

出　　处：《临床医学研究与实践》2017年第14期91-92,共2页Clinical Research and Practice

摘　　要：目的针对金双岐联合思密达治疗小儿腹泻的临床疗效及安全性进行分析。方法选取我院2013年5月至2016年5月收治的100例小儿腹泻患儿作为研究对象,按随机法将其分成观察组与对照组,每组50例患儿。对照组患儿在一般治疗基础上给予思密达口服,观察组患儿在一般治疗基础上采用金双岐联合思密达进行治疗,比较两组小儿腹泻患儿用药治疗一个疗程(5 d)后的临床疗效、症状、体征及不良反应发生情况。结果观察组小儿腹泻患儿的临床总有效率为98.00%,而对照组患儿的临床总有效率仅有80.00%,观察组患儿的总有效率明显高于对照组(P<0.05)。观察组患儿的退热时间(1.31±0.55)d明显短于对照组患儿的(2.54±1.45)d(P<0.05);两组小儿腹泻患儿都未发生明显的不良反应。结论使用金双岐联合思密达治疗小儿腹泻的临床疗效明显,没有明显的不良反应发生,可在各级医疗单位推广使用。Objective To explore the clinical effect and safety golden bifid and smecta in the treatment of infantile diarrhea. Methods One hundred children with infantile diarrhea from May 2013 to May 2016 were selected as the research objects, all the patients were randomly divided into observation group and control group, with 50 cases in each group. The patients in the control group received smecta based on the basis of conventional therapy and the observation group was given golden bifid based on the conventional therapy. After 1 course of treatment （5 d）, the curative effect, clinical symptoms, physical sign and complication incidence rate of the two groups were compared. Results The total clinical effect of the observation group was 98.00%, which was better than 80.00% of the control group （P〈0.05）; the antifebrile time of the observation group was （1.31：e0.55） d, which was shorter than （2.54_＋1.45） d of the control group, and the difference was significant （P〈0.05）. There was no obvious adverse reaction between the two groups. Conclusion Golden bifid and smecta in the treatment of infantile diarrhea has a remarkable curative effect with no obvious adverse reaction, which is worthy of popularization in all levels of medical units at all levels.

关 键 词：金双岐 思密达 小儿腹泻 临床疗效 

分 类 号：R725.7[医药卫生—儿科]